The global thin film drugs market size was estimated to be USD 23.18 billion in 2023 and is expected to reach at USD 70.07 billion by 2034 with a CAGR of 10.58% during the forecast period 2024-2034. Growing emphasis on addressing diverse chronic conditions, a rise in the occurrence of ailments such as schizophrenia, migraines, & opioid dependence, an escalating need for efficient thin film medications, heightened investments in the research & development of thin film drugs, an upsurge in research activities, advancing technology, and an increased dedication to developing innovative products are some of the key factors boosting the market growth.
Increased dedication to developing innovative products is predicted to boost the market growth during the forecast period. Thin-film drug delivery represents a progressive method of administering drugs, presenting a sophisticated alternative to conventional forms like capsules, tablets, and liquids. Pharmaceutical companies worldwide are actively exploring this emerging drug delivery system as an innovative means of administering medications. Thorough research into the pharmaceutical and pharmacological characteristics of the drug is imperative for formulating a thin film. This mode of drug delivery has demonstrated advantages for individuals facing challenges in swallowing tablets and those prone to nausea or vomiting. The rising popularity of this upcoming drug delivery approach is attributed to its rapid dissolution properties and the prolonged patent life cycle of existing products. For instance, in September 2022, TFF Pharmaceuticals, Inc., a biopharmaceutical company in the clinical stage, is dedicated to the development and commercialization of inventive drug products utilizing its patented Thin Film Freezing (TFF) technology platform. The company has disclosed the approval of numerous abstracts showcasing the application of its Thin Film Freezing Technology at the forthcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting.
By product, oral thin film was the highest revenue-grossing segment in the global thin film drugs market in 2023 owing to the growing count of pipeline products in various stages of development, increasing innovations in oral thin film drugs for the buccal cavity, and a rising trend of collaborations among market players. For instance, in March 2022, Cure Pharmaceutical and Milagro Pharmaceuticals have joined forces to register and market several over-the-counter (OTC) and medical compounds in Mexico. These compounds leverage Cure's patented drug delivery platform, CUREform, specifically designed for oral thin film (OTF). Additionally, transdermal thin film is predicted to grow at fastest CAGR during the forecast period owing to the increasing attention toward the creation of innovative therapies and a growing emphasis on the advancement of transdermal thin film delivery methods, particularly within the realm of pain management.
By indication, schizophrenia was the highest revenue-grossing segment in the global thin film drugs market in 2023 owing to the rising incidence of Schizophrenia, a growing elderly population, an increasing need for efficient drug delivery methods, and a surge in product approvals. For instance, in April 2022, The US FDA has granted approval to BioXcel Therapeutics for IGALM, a sublingual film designed for the immediate treatment of agitation linked to Schizophrenia or bipolar I or II disorder in adults. Patients can self-administer this under the guidance of a healthcare provider. Additionally, migraine is predicted to grow at fastest CAGR during the forecast period owing to a significant increase in the number of individuals experiencing migraines, a growing awareness regarding the efficacy of related medications, and an escalating emphasis on precision medicine.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global thin film drugs market in 2023 owing to the increased accessibility of drug products via retail channels and a rising trend of collaborations among market participants. For instance, in October 2022, IntelGenx Corp., a prominent pharmaceutical film drug delivery company, has entered into a collaboration with Atai Life Sciences to develop new formulations utilizing IntelGenx polymer film technologies. These formulations will leverage Atai's digital therapy to provide contextual monitoring and tailored support for patients. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in the adoption of online pharmacies and mail-order pharmacy services.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of major industry participants, the utilization of advanced technologies in pharmaceutical research and development to explore innovative drug delivery methods, a rising incidence of target diseases like schizophrenia, migraine, and opioid disorders, as well as the growing engagement of market players in strategic agreements, collaborations, partnerships, and similar initiatives to advance thin film drug development. For instance, in March 2022, TFF Pharmaceuticals and Catalent have joined forces to collaborate on the creation, testing, and production of a dry powder formulation employing thin film freezing technology. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in research & development efforts focused on thin-film drugs, a surge in government funding to support innovative drug delivery models, a growing geriatric population, heightened awareness of thin-film therapeutics, and an upward trend in collaborations among market players. For instance, in November 2022, Aptar Pharma and TFF Pharmaceuticals have entered into a collaboration. TFF Pharmaceuticals, a company dedicated to developing and bringing to market innovative drug products using its patented Thin Film Freezing technology platform, joined forces with Aptar Pharma. The collaboration's focus is on the development and testing of the administration of dry powder vaccines utilizing thin film freezing technology.
Increased dedication to developing innovative products is predicted to boost the market growth during the forecast period. Thin-film drug delivery represents a progressive method of administering drugs, presenting a sophisticated alternative to conventional forms like capsules, tablets, and liquids. Pharmaceutical companies worldwide are actively exploring this emerging drug delivery system as an innovative means of administering medications. Thorough research into the pharmaceutical and pharmacological characteristics of the drug is imperative for formulating a thin film. This mode of drug delivery has demonstrated advantages for individuals facing challenges in swallowing tablets and those prone to nausea or vomiting. The rising popularity of this upcoming drug delivery approach is attributed to its rapid dissolution properties and the prolonged patent life cycle of existing products. For instance, in September 2022, TFF Pharmaceuticals, Inc., a biopharmaceutical company in the clinical stage, is dedicated to the development and commercialization of inventive drug products utilizing its patented Thin Film Freezing (TFF) technology platform. The company has disclosed the approval of numerous abstracts showcasing the application of its Thin Film Freezing Technology at the forthcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting.
By product, oral thin film was the highest revenue-grossing segment in the global thin film drugs market in 2023 owing to the growing count of pipeline products in various stages of development, increasing innovations in oral thin film drugs for the buccal cavity, and a rising trend of collaborations among market players. For instance, in March 2022, Cure Pharmaceutical and Milagro Pharmaceuticals have joined forces to register and market several over-the-counter (OTC) and medical compounds in Mexico. These compounds leverage Cure's patented drug delivery platform, CUREform, specifically designed for oral thin film (OTF). Additionally, transdermal thin film is predicted to grow at fastest CAGR during the forecast period owing to the increasing attention toward the creation of innovative therapies and a growing emphasis on the advancement of transdermal thin film delivery methods, particularly within the realm of pain management.
By indication, schizophrenia was the highest revenue-grossing segment in the global thin film drugs market in 2023 owing to the rising incidence of Schizophrenia, a growing elderly population, an increasing need for efficient drug delivery methods, and a surge in product approvals. For instance, in April 2022, The US FDA has granted approval to BioXcel Therapeutics for IGALM, a sublingual film designed for the immediate treatment of agitation linked to Schizophrenia or bipolar I or II disorder in adults. Patients can self-administer this under the guidance of a healthcare provider. Additionally, migraine is predicted to grow at fastest CAGR during the forecast period owing to a significant increase in the number of individuals experiencing migraines, a growing awareness regarding the efficacy of related medications, and an escalating emphasis on precision medicine.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global thin film drugs market in 2023 owing to the increased accessibility of drug products via retail channels and a rising trend of collaborations among market participants. For instance, in October 2022, IntelGenx Corp., a prominent pharmaceutical film drug delivery company, has entered into a collaboration with Atai Life Sciences to develop new formulations utilizing IntelGenx polymer film technologies. These formulations will leverage Atai's digital therapy to provide contextual monitoring and tailored support for patients. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in the adoption of online pharmacies and mail-order pharmacy services.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of major industry participants, the utilization of advanced technologies in pharmaceutical research and development to explore innovative drug delivery methods, a rising incidence of target diseases like schizophrenia, migraine, and opioid disorders, as well as the growing engagement of market players in strategic agreements, collaborations, partnerships, and similar initiatives to advance thin film drug development. For instance, in March 2022, TFF Pharmaceuticals and Catalent have joined forces to collaborate on the creation, testing, and production of a dry powder formulation employing thin film freezing technology. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in research & development efforts focused on thin-film drugs, a surge in government funding to support innovative drug delivery models, a growing geriatric population, heightened awareness of thin-film therapeutics, and an upward trend in collaborations among market players. For instance, in November 2022, Aptar Pharma and TFF Pharmaceuticals have entered into a collaboration. TFF Pharmaceuticals, a company dedicated to developing and bringing to market innovative drug products using its patented Thin Film Freezing technology platform, joined forces with Aptar Pharma. The collaboration's focus is on the development and testing of the administration of dry powder vaccines utilizing thin film freezing technology.
Segmentation: Thin Film Drugs Market Report 2023 - 2034
Thin Film Drugs Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Transdermal Thin Film
- Oral Thin Film
Thin Film Drugs Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Opioid Dependence
- Schizophrenia
- Migraine
- Others
Thin Film Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Others
Thin Film Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Thin Film Drugs Market: Product Estimates & Trend Analysis
8. Thin Film Drugs Market: Indication Estimates & Trend Analysis
9. Thin Film Drugs Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Thin Film Drugs Market
12. Europe Global Thin Film Drugs Market
13. Asia Pacific Global Thin Film Drugs Market
14. Latin America Global Thin Film Drugs Market
15. MEA Global Thin Film Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Tesa SE (Tesa Labtec GmbH)
- Aquestive Therapeutics
- Sumitomo Dainippon Pharma Co. Ltd
- AdexPharma
- Pfizer Inc.
- Indivior PLC
- ZIM Laboratories Limited
- Solvay
- Novartis AG
- Intelgenx Corp
- ARx LLC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 23.18 Billion |
| Forecasted Market Value ( USD | $ 70.07 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
